[{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"06560225-2b42-48b3-bbbc-b9ae314d8a0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040231","created_at":"2021-02-01T11:53:19.132Z","updated_at":"2024-07-02T16:34:26.088Z","phase":"Phase 1","brief_title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","source_id_and_acronym":"NCT04040231","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"9bdad34e-56d0-48b9-af40-2c4c90d60427","acronym":"WP42004","url":"https://clinicaltrials.gov/study/NCT04580121","created_at":"2021-06-30T14:53:56.262Z","updated_at":"2024-07-02T16:34:59.484Z","phase":"Phase 1","brief_title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","source_id_and_acronym":"NCT04580121 - WP42004","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/04/2020","start_date":" 11/04/2020","primary_txt":" Primary completion: 08/09/2023","primary_completion_date":" 08/09/2023","study_txt":" Completion: 08/09/2023","study_completion_date":" 08/09/2023","last_update_posted":"2024-06-03"},{"id":"84516b21-8265-457c-a480-fa67aca332aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837196","created_at":"2021-04-08T12:52:25.748Z","updated_at":"2024-07-02T16:35:01.857Z","phase":"Phase 1/2","brief_title":"Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen","source_id_and_acronym":"NCT04837196","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • BRAF • ALK • WT1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • BRAF • ALK • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP7517"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-23"},{"id":"5fc95c78-0abd-4ca1-9e8e-6011739ca3e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284228","created_at":"2021-01-18T20:47:52.551Z","updated_at":"2024-07-02T16:35:23.484Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT","source_id_and_acronym":"NCT04284228","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-15"},{"id":"2b60a198-36bb-4737-9740-9e0001718260","acronym":"","url":"https://clinicaltrials.gov/study/NCT01758328","created_at":"2021-01-18T07:43:30.186Z","updated_at":"2024-07-02T16:35:24.465Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT01758328","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan • ATA520"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"30e6b0d2-9ae8-42e8-950a-d7ffc20b493b","acronym":"WIZARD201G","url":"https://clinicaltrials.gov/study/NCT03149003","created_at":"2021-06-30T14:53:13.951Z","updated_at":"2024-07-02T16:35:29.166Z","phase":"Phase 3","brief_title":"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy","source_id_and_acronym":"NCT03149003 - WIZARD201G","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" MGMT • HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["MGMT • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2023-11-15"},{"id":"552ca11f-790a-4b84-becf-793c8ecee83b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498665","created_at":"2021-01-18T12:02:59.664Z","updated_at":"2024-07-02T16:35:29.249Z","phase":"Phase 1","brief_title":"A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT02498665","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" HLA-A • MUC16","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2023-11-14"},{"id":"343f189d-c6cb-4a8b-b082-0b802260f284","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320809","created_at":"2022-04-11T13:52:57.991Z","updated_at":"2024-07-02T16:35:31.834Z","phase":"Phase 1","brief_title":"Study of 3D189 in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05320809","lead_sponsor":"3D Medicines","biomarkers":" WT1","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-25"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"95852f2d-c3f9-49a8-9023-dcdaab70f2d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750891","created_at":"2021-01-18T13:28:43.111Z","updated_at":"2024-07-02T16:36:13.147Z","phase":"Phase 1/2","brief_title":"A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas","source_id_and_acronym":"NCT02750891","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" PD-L1 • WT1","pipe":" | ","alterations":" PD-L1 expression • HLA-A*24","tags":["PD-L1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-04-12"},{"id":"d14351b0-6a7c-4a76-937b-a44735e97526","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436252","created_at":"2021-02-01T11:52:50.145Z","updated_at":"2024-07-02T16:36:13.189Z","phase":"Phase 1/2","brief_title":"Study of DSP-7888 in Patients With Myelodysplastic Syndrome","source_id_and_acronym":"NCT02436252","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" HLA-A • WT1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-04-12"},{"id":"a82c37b0-b7de-4909-9ed6-4017ba0331ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620633","created_at":"2021-01-18T02:18:25.353Z","updated_at":"2024-07-02T16:36:33.932Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation","source_id_and_acronym":"NCT00620633","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":" | ","alterations":" WT1 overexpression","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATA520"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2008","start_date":" 02/08/2008","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2021-03-02"},{"id":"68b4f52e-1dcf-41a8-96f4-f19ebb8b9a74","acronym":"","url":"https://clinicaltrials.gov/study/NCT02405338","created_at":"2021-01-18T11:29:06.551Z","updated_at":"2024-07-02T16:36:43.521Z","phase":"Phase 1/2","brief_title":"DC Vaccination for Post-remission Therapy in AML","source_id_and_acronym":"NCT02405338","lead_sponsor":"Medigene AG","biomarkers":" WT1 • PRAME","pipe":"","alterations":" ","tags":["WT1 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CVT-DC-01"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-07-07"},{"id":"baa7e829-6923-4d37-b1b8-aed8bbc1d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827137","created_at":"2021-01-29T07:04:33.744Z","updated_at":"2024-07-02T16:36:51.495Z","phase":"","brief_title":"WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT01827137","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" IFNG • WT1 • CD4","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["IFNG • WT1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Unknown status","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2020-01-10"},{"id":"b294fdf4-c8ff-4ead-9de3-8545b0b729c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01621542","created_at":"2021-02-01T11:52:30.876Z","updated_at":"2024-07-02T16:36:58.056Z","phase":"Phase 1","brief_title":"Clinical Study of WT2725 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01621542","lead_sponsor":"Sunovion","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT2725"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/31/2012","start_date":" 07/31/2012","primary_txt":" Primary completion: 05/17/2017","primary_completion_date":" 05/17/2017","study_txt":" Completion: 05/17/2017","study_completion_date":" 05/17/2017","last_update_posted":"2019-07-17"},{"id":"cdbb0b72-4989-4bfe-b215-24f0d0781366","acronym":"","url":"https://clinicaltrials.gov/study/NCT01890980","created_at":"2021-01-18T08:29:29.880Z","updated_at":"2024-07-02T16:36:59.765Z","phase":"Phase 2","brief_title":"Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134","source_id_and_acronym":"NCT01890980","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" WT1 • CSF2","pipe":"","alterations":" ","tags":["WT1 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2019-05-10"},{"id":"937cd282-98ca-4cd4-be39-75fd046925ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266083","created_at":"2021-01-18T05:07:05.651Z","updated_at":"2024-07-02T16:37:04.963Z","phase":"Phase 2","brief_title":"WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT01266083","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" FLT3 • NPM1 • WT1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2018-11-30"},{"id":"0319ca73-9379-4e46-9216-1095fcc78f0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01265433","created_at":"2021-01-18T05:06:32.789Z","updated_at":"2024-07-02T16:37:05.585Z","phase":"Phase 2","brief_title":"WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy","source_id_and_acronym":"NCT01265433","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" WT1 • CSF2","pipe":"","alterations":" ","tags":["WT1 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 12/21/2010","start_date":" 12/21/2010","primary_txt":" Primary completion: 07/25/2017","primary_completion_date":" 07/25/2017","study_txt":" Completion: 07/25/2017","study_completion_date":" 07/25/2017","last_update_posted":"2018-11-05"},{"id":"11bb818d-40e6-4fec-af67-e5c9e6902773","acronym":"","url":"https://clinicaltrials.gov/study/NCT02550535","created_at":"2021-02-01T11:52:52.801Z","updated_at":"2024-07-02T16:37:06.491Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS \u0026 AML Patients","source_id_and_acronym":"NCT02550535","lead_sponsor":"Cell Medica Ltd","biomarkers":" WT1","pipe":" | ","alterations":" HLA-A*02:01","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CMD-602"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-10-02"}]